רופילק 300

Land: Israel

Sprache: Hebräisch

Quelle: Ministry of Health

Wirkstoff:

ANTI-D IMMUNOGLOBULINS

Verfügbar ab:

CSL BEHRING LTD., ISRAEL

ATC-Code:

J06BB01

Darreichungsform:

תמיסה להזרקה

Zusammensetzung:

ANTI-D IMMUNOGLOBULINS 150 MCG/ML

Verabreichungsweg:

תוך-שרירי, תוך-ורידי

Verschreibungstyp:

מרשם נדרש

Hergestellt von:

CSL BEHRING AG, SWITZERLAND

Therapiegruppe:

ANTI-D (RH) IMMUNOGLOBULIN

Therapiebereich:

ANTI-D (RH) IMMUNOGLOBULIN

Anwendungsgebiete:

Prophylaxis of Rh (D) immunisation in Rh (D)-negative women: Anti-D immune globulin is administered for the prevention of Rh (D) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. Treatment is not necessary when it is assured that the child or the father are Rh (D)- negative. Criteria for a rhesus-incompatible pregnancy and the administration of anti-D immune globulin are : a) the mother is Rh (D) -negative b) the child is either Rh (D)-positive Rh (D)weak - positive or its rhesus type is not known. Routine antepartum prophylaxis : To prevent Rh (D) immunisation due to spontaneous fetomaternal haemorrhage (FMH) during the last trimester of pregnancy. Postpartum prophylaxis To prevent Rh (D) immunisation of the Rh (D)-negative mother following delivery of a Rh (D)-positive child. Complications of pregnancy: Interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

Berechtigungsdatum:

2023-02-28